Navigation Links
Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast'
Date:8/10/2011

MUMBAI, August 10, 2011 /PRNewswire/ --


  • Revamilast is a PDE4 inhibitor, under development for Asthma, Rheumatoid Arthritis and other inflammatory disorders
  • The molecule successfully completed pre-clinical trials and Phase I studies
    • Phase I studies on healthy volunteers were carried out mainly in the UK
  • Glenmark has initiated global  Phase IIb studies for both indications in Europe and Asia
  • Huge unmet medical need as globally they are over 300 million Asthma patients and over 20 million Rheumatoid Arthritis patients

Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as  Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases. The Phase IIb studies that will be carried out will help establish the efficacy and safety of the molecule and will also provide dose range finding data for Revamilast.

Dr. Steffen Stuerzebecher, President & Chief Medical Officer, Glenmark Pharmaceuticals Ltd said "The clinical trials and the animal studies data for Revamilast are promising for both indications i.e. Asthma and Rheumatoid Arthritis. There is a huge unmet need for both these chronic medical conditions globally. For Glenmark, this is a significant development as we have built on more than a decade of experience in the PDE 4 space to progress an exciting molecule to Phase II human trials."

In Phase I studies carried out mainly in the United Kingdom, nearly 150 healthy volunteers have been dosed and no Serious Adverse Events have been noted. The pharmacodynamic evaluation in healthy hum
'/>"/>

SOURCE Glenmark Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Glenmark Announces the Discovery of a Novel Chemical Entity GRC 17536, a TRPA1 Receptor Antagonist, a Potential First-in-Class Molecule Globally
2. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
3. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London
4. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
5. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
6. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
7. GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine
8. CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
9. Metabolex Initiates Phase 2 Trial of Arhalofenate
10. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
11. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 03, 2015 Typical racks for laboratory ... heights and depths often taking up unnecessary room in ... Ultra Low 5 Box Freezer Racks offer a ... existing freezer storage boxes and freezers. , “These ... multiple experiments or multiple people because users can configure ...
(Date:6/3/2015)... , June 3, 2015  HireLifeScience.com, the premier ... will host its 6 th annual career ... at Raritan Center in Edison, NJ ... include Novo Nordisk, Covance, Actavis and AstraZeneca.  Additional ... be exhibiting are Johnson & Johnson, MedImmune, DSM ...
(Date:6/3/2015)... Innovative biomass supply chain industry leader, Genera Energy ... first annual Advanced Bioeconomy Feedstocks Conference (ABFC) ... Orleans, June 9-10, the conference brings together leaders in ... advancements of feedstock by discussing pressing issues such as ... and more. , As a tier-one sponsor, ...
(Date:6/3/2015)... REYKJAVIK, Iceland , June 3, 2015 /PRNewswire/ ... the genome to improve health worldwide, today announced that ... (GeL) to provide clinical interpretation of the whole genome ... part of the first phase of the 100,000 Genomes ... WuXi NextCODE will deploy its unique ...
Breaking Biology Technology:Freezer Space Can Now Be Configured Your Way with New Modular Freezer Racks 2AstraZeneca Added as Sponsor for Industry Leading Life Science Hiring Event 2Genera to Sponsor Advanced Bioeconomy Feedstocks Conference 2015 2Genera to Sponsor Advanced Bioeconomy Feedstocks Conference 2015 3WuXi NextCODE Wins Genomics England Clinical Interpretation Tender in both Rare Disease and Cancer 2
... Therapeutics,(Amex: CXM ) announced positive findings from ... University, which demonstrated highly,efficient uptake of DNA-based vectors ... flow as a result of blockage of the,coronary ... model,analogous to a heart attack or acute myocardial ...
... States Passed Laws in 2007, but 26 Still Earn D,s or F,s on ... Legislation Report Card, ... U.S. population is now covered by state laws that,require insurance providers to cover ... by a coalition of 11 leading,public health groups. The enactment of new coverage ...
... SAN FRANCISCO, March 11 VIA Pharmaceuticals,(Nasdaq: ... development of,compounds for the treatment of cardiovascular disease, ... and James G. Stewart, senior,vice president and chief ... 2008 Cowen and Company 28th Annual Health Care ...
Cached Biology Technology:Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 2Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 3Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 4Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 5Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 6Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 7Colon Cancer Screening Laws Now Cover Half of U.S. Population 2Colon Cancer Screening Laws Now Cover Half of U.S. Population 3Colon Cancer Screening Laws Now Cover Half of U.S. Population 4Colon Cancer Screening Laws Now Cover Half of U.S. Population 5
(Date:5/21/2015)... -- According to a new market ... Services), by Applications (Surveillance (Airborne, Maritime, Land), Threat ... & Defense & Commercial) - Global Forecast to ... expected to grow from $7252.0 Million in 2015 ... Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market"  report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ...
(Date:5/19/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... who are more extroverted and less anxious are more likely ... are introverted or anxious. Published early online in the ... mothers with certain personalities may need additional support and education ... breastfeeding. Breastfeeding is important for the health of ...
... -- The colorful restaurant menus that thousands of tourists bring ... of island vacations. They also contain valuable data that ... important fisheries in the Aloha State. The scientists are ... fill a 45-year gap in official records of wild fish ...
... The results of a large-scale analysis of the association between ... most common cancers are not associated with DNA viruses. ... Journal of Virology , challenge earlier studies suggesting as ... For years scientists believed viruses played a role in ...
Cached Biology News:Personality may affect a new mother's decision to breastfeed 2Seafood menus from Hawaii reflect long-term ocean changes 2Percentage of cancers linked to viruses potentially overestimated 2
Mycoplasma tested...
...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... supernates and serum. Each kit contains sufficient ... 96-well plates, provided that the following conditions ...
Blimp-1 (H-150)...
Biology Products: